Neoadjuvant Anti-Angiogenesis Therapy for Prostate Cancer
Abstract
This protocol is designed to evaluate the effects of combined anti-angiogenesis and androgen ablation therapy in men at high risk for recurrence after radical prostatectomy. Both clinical (i.e., pathologic, disease-free survival, safety) and molecular factors will be evaluated. A clinical trial to test the effectiveness of this therapy was initiated in January 2003. After a slow initial accrual recruitment has been increasing steadily. It is still too early to evaluate the anti-cancer efficacy of combined androgen ablation and anti-angiogenesis therapy, however, the drug has been well tolerated and there have been no surgically related complications. As more men are enrolled and undergo treatment, the author will be able to evaluate the effects of this therapy on the natural history of prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2003
- Accession Number
- ADA419174
Entities
People
- Mitchell H. Sokoloff
Organizations
- University of Chicago